Hudson Bay Capital Management LP Acquires 128,256 Shares of Astrazeneca Plc $AZN

Key Points

• Hudson Bay Capital Management LP increased its AstraZeneca stake by 40.5%, buying 128,256 shares to hold 444,874 shares valued at about $34.13 million.
• AstraZeneca declared a $1.595 dividend payable on March 23, with shareholders of record and the ex-dividend date on February 20.
• Market snapshot: AZN was trading near $188.42 with a market cap of about $292.2 billion, a 52-week range of $122.48–$212.71, and a consensus analyst rating of "Moderate Buy".

Hudson Bay Capital Management LP boosted its holdings in shares of Astrazeneca Plc (NYSE:AZN - Free Report) by 40.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 444,874 shares of the company's stock after acquiring an additional 128,256 shares during the period. Hudson Bay Capital Management LP's holdings in Astrazeneca were worth $34,131,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Triumph Capital Management acquired a new stake in shares of Astrazeneca during the third quarter worth $25,000. Rakuten Investment Management Inc. bought a new stake in Astrazeneca in the third quarter valued at about $31,000. JPL Wealth Management LLC acquired a new position in Astrazeneca in the third quarter valued at about $35,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in Astrazeneca by 144.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company's stock valued at $36,000 after buying an additional 275 shares during the period. Finally, VSM Wealth Advisory LLC bought a new position in Astrazeneca during the second quarter worth about $33,000. Institutional investors own 20.35% of the company's stock.

Astrazeneca Trading Down 1.5%

NYSE:AZN opened at $188.42 on Thursday. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 0.51. Astrazeneca Plc has a fifty-two week low of $122.48 and a fifty-two week high of $212.71. The stock has a market cap of $292.22 billion, a PE ratio of 20.88, a price-to-earnings-growth ratio of 1.44 and a beta of 0.32.

Astrazeneca Announces Dividend

The business also recently declared a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be paid a $1.595 dividend. The ex-dividend date of this dividend is Friday, February 20th. This represents a yield of 156.0%. Astrazeneca's payout ratio is presently 66.26%.

Wall Street Analysts Forecast Growth

AZN has been the subject of several analyst reports. HSBC restated a "buy" rating and set a $108.00 target price on shares of Astrazeneca in a research report on Wednesday, December 10th. Barclays reissued an "overweight" rating on shares of Astrazeneca in a research note on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Astrazeneca in a report on Friday, February 6th. Citigroup began coverage on shares of Astrazeneca in a research note on Tuesday, January 27th. They issued a "buy" rating for the company. Finally, Morgan Stanley reissued an "overweight" rating and set a $103.00 price target on shares of Astrazeneca in a research report on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Astrazeneca presently has an average rating of "Moderate Buy" and a consensus target price of $95.75.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.